T1	Participants 38 124	zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3
T2	Participants 300 426	zidovudine (AZT)-treated asymptomatic human immunodeficiency virus (HIV)-infected subjects with 200-500 CD4 cells/mm3 at entry
T3	Participants 432 444	352 subjects
